Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushen Qingtou Fang is a Traditional Chinese Medicine (TCM) herbal formula developed by researchers at Guangzhou University of Traditional Chinese Medicine for the treatment of chronic hepatitis B (CHB). The recipe is formulated based on the TCM principles of tonifying the kidney ("Bushen") and clearing or venting pathogenic factors ("Qingtou"), which are believed to address the underlying deficiencies and viral persistence in chronic HBV carriers. It is typically administered as decoction-free granules. In clinical research, it has been evaluated in randomized, double-blind trials to assess its efficacy in promoting HBeAg seroconversion and reducing viral load in chronic hepatitis B virus carriers, often compared against other TCM strategies such as the Bushen Jianpi recipe.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bushen Qingtou Fang.